Antibody-mediated RejectionPhase 2NCT03444103
A Pilot Trial of Clazakizumab in Late ABMR
A Phase 2 study testing Clazakizumab / Clazakizumab in people with Antibody-mediated Rejection, run by Medical University of Vienna at 2 sites in 2 countries.
Trial summary
This bi-center study (Medical University of Vienna \& Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of humanized anti-IL-6 monoclonal antibody clazakizumab in kidney transplant recipients with… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Antibody-mediated Rejection
- What is being tested?
- Clazakizumab / Clazakizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 16 Jan 2018to 30 Jun 2020
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntary written informed consent
- Age >18 years
- Functioning living or deceased donor allograft after ≥365 days post-transplantation
- eGFR >30 ml/min/1.73 m2
- Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
- Acute/active or chronic/active ABMR (±C4d in PTC) according to Banff 2013/2015
- Molecular ABMR score (ABMRpm) ≥0.2
Who cannot join
- Patients actively participating in another clinical trial
- Age ≤18 years
- Female subject is pregnant or lactating
- Index biopsy results:
- T-cell-mediated rejection classified Banff grade ≥I
- De novo or recurrent severe thrombotic microangiopathy
Show all 22Show fewer
- Polyoma virus nephropathy
- De novo or recurrent glomerulonephritis
- Acute rejection treatment <3 month before screening
- Acute deterioration of graft function (eGFR decline within 1-3 months >25%)
- Nephrotic range proteinuria >3500 mg/g protein/creatinine ratio
- Active viral, bacterial or fungal infection precluding intensified immunosuppression
- Active malignant disease precluding intensified immunosuppressive therapy
- Abnormal liver function tests (ALT, AST, bilirubin > 1.5 x upper limit of normal)
- Other significant liver disease
- Latent or active tuberculosis (positive QuantiFERON-TB-Gold test, Chest X-ray)
- Administration of a live vaccine within 6 weeks of screening
- Neutropenia (<1 G/L) or thrombocytopenia (<100 G/L)
- History of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease
- Allergy against proton pump inhibitors
- History of alcohol or illicit substance abuse
- Serious medical or psychiatric illness likely to interfere with participation in the study
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
About this study
Official title: Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
This bi-center study (Medical University of Vienna \& Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of humanized anti-IL-6 monoclonal antibody clazakizumab in kidney transplant recipients with late antibody-mediated rejection (ABMR). The study is designed as a phase 2 trial and has two subsequent sub-parts, a randomized placebo-controlled trial (part A) of 12 weeks, where recipients are allocated to receive either anti-IL-6 antibody clazakizumab (n=10) or placebo (n=10), followed by an open-label prospective study, where all 20 study patients will receive clazakizumab for a period of 40 weeks. Study protocol biopsies will be performed at the end of part A and part B.
Read the detailed description
Part A:
Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.
Part B:
After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.
- Conditions
- Antibody-mediated Rejection
- Being tested
- Clazakizumab / Clazakizumab, Placebo / Clazakizumab
- Keywords
- IL-6 blockade
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clazakizumab / ClazakizumabDrug
Also called Anti-IL-6 antibody
Humanized monoclonal anti-IL-6 antibody
Placebo / ClazakizumabDrug
Also called Saline
0.9% Saline
| Study group | Role | What they receive |
|---|---|---|
| Clazakizumab / Clazakizumab | Active comparator | Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months). Receives: Drug: Clazakizumab / Clazakizumab |
| Placebo / Clazakizumab | Placebo comparator | Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months). Receives: Drug: Placebo / Clazakizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of adverse events and severe adverse events (AE's, SAE's)
Serious and Non-Serious adverse events probably or possibly attributable to clazakizumab
Measured: 12 months
Secondary outcomes (26)
Anti-clazakizumab antibodies in serum
- Concentration of anti-clazakizumab antibodies in serum (ng/mL)
Measured: At 0, 12 and 52 weeks
Clazakizumab serum concentration
- Total clazakizumab serum concentration (ng/mL)
Measured: At 0, 12 and 52 weeks
Pantoprazole serum concentration
- Effect of clazakizumab on pantoprazole serum concentration (nanogram per mL)
Measured: At 0, 12 and 52 weeks
Protocol biopsy results - microcirculation inflammation
- Microcirculation inflammation (g+ptc score), scale 0-3, higher = worse prognosis
Measured: At week 11 and at week 52
Protocol biopsy results - chronic damage
- Transplant glomerulopathy (cg) and interstitial fibrosis/tubular atrophy (IFTA) scores, scale 0-3, higher = worse prognosis
Measured: At week 11 and at week 52
Protocol biopsy results - molecular signs of ABMR
- Molecular ABMR score (molecular microscope, MMDx), scale 0-1 in 0.1 steps, higher = worse prognosis
Measured: At week 11 and at week 52
Protocol biopsy results - ABMR phenotype
- Archetype analysis of gene expression profiles (molecular microscope, MMDx), ABMR archetype score, scale 0-1 in 0.1 steps, higher = worse prognosis
Measured: At week 11 and at week 52
Anti-HLA antibody levels - antibody strength
- Maximum and sum of mean fluorescence intensity (MFI) of DSA (Luminex) - higher is worse
Measured: At 0, 12 and 52 weeks
Anti-HLA antibody levels - number of DSA
- Number of DSA (Luminex) - more is worse
Measured: At 0, 12 and 52 weeks
Anti-HLA antibody levels - broadness of antibody reactivity
- Broadness of sensitization (virtual PRA, Luminex), scale: %, higher = worse
Measured: At 0, 12 and 52 weeks
Allograft function - eGFR
- Estimated GFR (CKD-EPI, mL/min/1.73m2)
Measured: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Allograft function - protein excretion in spot urine
- Urinary protein excretion in spot urine (protein/creatinine ratio in mg/g)
Measured: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Total IgG concentration
- Nephelometry, mg/dL
Measured: At 0, 12 and 52 weeks
Total IgM concentration
- Nephelometry, mg/dL
Measured: At 0, 12 and 52 weeks
Total IgA concentration
- Nephelometry, mg/dL
Measured: At 0, 12 and 52 weeks
IgG subclass 1 (IgG1)
- ELISA, mg/dL
Measured: At 0, 12 and 52 weeks
IgG subclass 2 (IgG2)
- ELISA, mg/dL
Measured: At 0, 12 and 52 weeks
IgG subclass 3 (IgG3)
- ELISA, mg/dL
Measured: At 0, 12 and 52 weeks
IgG subclass 4 (IgG4)
- ELISA, mg/dL
Measured: At 0, 12 and 52 weeks
Effect on leukocyte subsets in peripheral blood
- Fluorescence intensity (0 to no upper limit)
Measured: At 0, 12 and 52 weeks
Cytokine patterns and endothelial activation/injury markers in serum
- Luminex bead panels, mean fluorescence intensities (MFI)
Measured: At 0, 12 and 52 weeks
Effect on IL-6 gene expression in peripheral blood cells
rtPCR
Measured: At 0, 12 and 52 weeks
Effect on IL-6R gene expression in peripheral blood cells
rtPCR
Measured: At 0, 12 and 52 weeks
Patient survival
Death: number of events, time to event
Measured: 12 months
Graft survival
Graft loss: number of events, time to event
Measured: 12 months
Occurrence of biopsy-proven acute rejection necessitating rejection treatment
Number of anti-rejection treatments with a substance other than the study drug
Measured: At week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2018
- Study start16 Jan 2018
- Primary completion30 Jun 2020
- Study completion30 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Antibody-mediated RejectionStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- CSL Behring, University of Alberta, Charite University, Berlin, Germany
- Responsible party
- Principal investigator, Farsad Eskandary, Medical University of Vienna
- Investigators
- Bernd Jilma, MD, Principal investigator, Department of Clinical Pharmacology, Medical University Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03444103
- Sponsor's protocol ID
- EK1428/2017
- Other IDs
- 2017-001604-30, 2017
- Status last verified
- Sep 2020
- First submitted
- 16 Jan 2018
- Last updated
- 9 Sep 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
PubMed 27059799Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10.
PubMed 28199785Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Bohmig GA. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.
PubMed 29242250Mayer KA, Doberer K, Halloran PF, Budde K, Haindl S, Muhlbacher J, Eskandary F, Viard T, Casas S, Jilma B, Bohmig GA. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10. Transplant Direct. 2022 Nov 10;8(12):e1406. doi: 10.1097/TXD.0000000000001406. eCollection 2022 Dec.
PubMed 36382130Muhlbacher J, Schorgenhofer C, Doberer K, Durr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Bohmig GA. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8.
PubMed 34153143Eskandary F, Durr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Muhlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Bohmig GA. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.
PubMed 30635033
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
- ClinicalTrials.gov ID
- NCT03444103
- Acronym / sponsor ID
- EK1428/2017
- Conditions
- Antibody-mediated Rejection
- Keywords
- IL-6 blockade
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Collaborators
- CSL Behring, University of Alberta, Charite University, Berlin, Germany
- Study start
- 16 Jan 2018 (actual)
- Primary completion
- 30 Jun 2020 (actual)
- Study completion
- 30 Jun 2020 (actual)
- First posted
- 23 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This bi-center study (Medical University of Vienna \& Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of humanized anti-IL-6 monoclonal antibody clazakizumab in kidney transplant recipients with late antibody-mediated rejection (ABMR). The study is designed as a phase 2 trial and has two subsequent sub-parts, a randomized placebo-controlled trial (part A) of 12 weeks, where recipients are allocated to receive either anti-IL-6 antibody clazakizumab (n=10) or placebo (n=10), followed by an open-label prospective study, where all 20 study patients will receive clazakizumab for a period of 40 weeks. Study protocol biopsies will be performed at the end of part A and part B.
Detailed description
Part A:
Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.
Part B:
After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Clazakizumab / Clazakizumab | Active comparator | Drug: Clazakizumab / ClazakizumabMonthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months). |
| Placebo / Clazakizumab | Placebo comparator | Drug: Placebo / ClazakizumabMonthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months). |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Voluntary written informed consent
- Age >18 years
- Functioning living or deceased donor allograft after ≥365 days post-transplantation
- eGFR >30 ml/min/1.73 m2
- Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
Key exclusion criteria (22 listed)
- Patients actively participating in another clinical trial
- Age ≤18 years
- Female subject is pregnant or lactating
- Index biopsy results:
- T-cell-mediated rejection classified Banff grade ≥I
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clazakizumab / ClazakizumabAlso: Anti-IL-6 antibodyHumanized monoclonal anti-IL-6 antibody | Drug | Clazakizumab / Clazakizumab |
| Placebo / ClazakizumabAlso: Saline0.9% Saline | Drug | Placebo / Clazakizumab |
Primary outcome
Number of adverse events and severe adverse events (AE's, SAE's)
Time frame: 12 months
Serious and Non-Serious adverse events probably or possibly attributable to clazakizumab
26 secondary outcomes
Anti-clazakizumab antibodies in serum
Time frame: At 0, 12 and 52 weeks
Clazakizumab serum concentration
Time frame: At 0, 12 and 52 weeks
Pantoprazole serum concentration
Time frame: At 0, 12 and 52 weeks
Protocol biopsy results - microcirculation inflammation
Time frame: At week 11 and at week 52
Protocol biopsy results - chronic damage
Time frame: At week 11 and at week 52
Protocol biopsy results - molecular signs of ABMR
Time frame: At week 11 and at week 52
Protocol biopsy results - ABMR phenotype
Time frame: At week 11 and at week 52
Anti-HLA antibody levels - antibody strength
Time frame: At 0, 12 and 52 weeks
Anti-HLA antibody levels - number of DSA
Time frame: At 0, 12 and 52 weeks
Anti-HLA antibody levels - broadness of antibody reactivity
Time frame: At 0, 12 and 52 weeks
Allograft function - eGFR
Time frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Allograft function - protein excretion in spot urine
Time frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Total IgG concentration
Time frame: At 0, 12 and 52 weeks
Total IgM concentration
Time frame: At 0, 12 and 52 weeks
Total IgA concentration
Time frame: At 0, 12 and 52 weeks
IgG subclass 1 (IgG1)
Time frame: At 0, 12 and 52 weeks
IgG subclass 2 (IgG2)
Time frame: At 0, 12 and 52 weeks
IgG subclass 3 (IgG3)
Time frame: At 0, 12 and 52 weeks
IgG subclass 4 (IgG4)
Time frame: At 0, 12 and 52 weeks
Effect on leukocyte subsets in peripheral blood
Time frame: At 0, 12 and 52 weeks
Cytokine patterns and endothelial activation/injury markers in serum
Time frame: At 0, 12 and 52 weeks
Effect on IL-6 gene expression in peripheral blood cells
Time frame: At 0, 12 and 52 weeks
Effect on IL-6R gene expression in peripheral blood cells
Time frame: At 0, 12 and 52 weeks
Patient survival
Time frame: 12 months
Graft survival
Time frame: 12 months
Occurrence of biopsy-proven acute rejection necessitating rejection treatment
Time frame: At week 52
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2020.
- Background: PubMed 27059799Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
- Background: PubMed 28199785Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10.
- Background: PubMed 29242250Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Bohmig GA. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.
- Derived from this study: PubMed 36382130Mayer KA, Doberer K, Halloran PF, Budde K, Haindl S, Muhlbacher J, Eskandary F, Viard T, Casas S, Jilma B, Bohmig GA. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10. Transplant Direct. 2022 Nov 10;8(12):e1406. doi: 10.1097/TXD.0000000000001406. eCollection 2022 Dec.
- Derived from this study: PubMed 34153143Muhlbacher J, Schorgenhofer C, Doberer K, Durr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Bohmig GA. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8.
- Derived from this study: PubMed 30635033Eskandary F, Durr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Muhlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Bohmig GA. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.
- Vienna Transplant and Complement Laboratory (VIETAC) websiteLink provided by the sponsor.
- Vitaeris websiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Antibody-mediated Rejection
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
RecruitingPhase 1
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Lung Transplantation
Enrolling by invitationPhase 3
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Antibody-mediated Rejection, Microvascular Inflammation
Active, not recruitingPhase 2
Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial
Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
RecruitingPhase 1
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
Kidney Transplant Rejection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bernd Jilma, MD principal investigator
Department of Clinical Pharmacology, Medical University Vienna
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Clazakizumab / Clazakizumab in people with Antibody-mediated Rejection, run by Medical University of Vienna at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Austria, Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of adverse events and severe adverse events (AE's, SAE's) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03444103, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2020.